The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.

Moderna Inc.'s stock tumbled 4% Thursday, after a report that health officials are reviewing a contract the company won from the Biden administration to support its efforts to develop a bird-flu ...

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.

US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker.

Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services ...

The Trump administration has canceled an upcoming meeting of the Food and Drug Administration’s vaccine advisory committee, a ...

Moderna’s reliance on its COVID vaccine for revenue has become a vulnerability as sales decline and the company invests heavily in its product pipeline. The bird flu vaccine contract was expedited due ...

The back-to-back high-level disruptions in vaccine policy under Robert F. Kennedy Jr comes as the U.S. records its first ...

Moderna (MRNA) stock is reacting to reports of the US Department of Health and Human Services (HHS) reconsidering its bird flu vaccine deal with the drug maker. Yahoo Finance senior health reporter ...

The U.S. government awarded Moderna $590 million in January to advance the development of its bird flu vaccine ...